Scaling up bacterial minicell production

扩大细菌小细胞生产

基本信息

  • 批准号:
    7481459
  • 负责人:
  • 金额:
    $ 13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-06-01 至 2009-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): "Scaling up bacterial minicell production" This project is focused around scaling up bacterial minicell production to meet projected market demands of any of Vaxiion minicell-based products. We propose to construct a panel of minicell producing strains from E. coli, Salmonella spp, Shigella spp, and Campylobacter using a single genetic approach that has been optimized to maximize minicell productions across the panel. The first aim of this proposal is to identify exactly which genes within the highly conserved ftsQAZ need to be over expressed to obtain maximum minicell production. The second aim of this proposal is to introduce, using the same procedure and materials in parallel, the gene combination identified in the previous effort on to the chromosome of each of the organisms listed. These strains will then be tested for production capacity in growth conditions optimized in small scale (<10L) fermentation runs on an experimental basis in conjunction with a CMO that will eventually be handling all future large scale (<100L) production. PUBLIC HEALTH RELEVANCE: "Scaling up bacterial minicell production" Vaxiion Therapeutics, Inc. Is focused on brining several proprietary bacterial minicell-based products to market. Without going into much detail here, Vaxiion has positioned the bacterial minicell platform technology to be used in vaccine development, targeted delivery of cancer therapeutics, and early stage in vivo targeted tumor bio-imaging. While all three programs are making progress in their respective stages of preclinical development, there remains one vital issue that all of these would be products have in common that must be addressed if minicells are ever to be brought to market. The issue is the ability of Vaxiion to scale up both production and purification to meet projected demand for all of these products. The funds, if awarded for this Phase I SBIR grant proposal will be used to address production, while Phase II would focus primarily on large scale production and purification.
描述(由申请人提供):“按比例扩大细菌小细胞生产”该项目的重点是按比例扩大细菌小细胞生产,以满足任何基于Vaxiion小细胞的产品的预计市场需求。我们建议从大肠杆菌中构建一组产生小细胞的菌株。大肠杆菌、沙门氏菌属、志贺氏菌属和弯曲杆菌,使用单一遗传方法,该方法已被优化以最大化整个面板的小细胞产量。该建议的第一个目的是准确鉴定高度保守的ftsQAZ中哪些基因需要过表达以获得最大的小细胞产量。本提案的第二个目的是,使用相同的程序和材料,平行地将在先前的努力中鉴定的基因组合引入到所列的每种生物的染色体上。然后将在小规模(<10 L)发酵运行中优化的生长条件下,结合最终将处理所有未来大规模(<100 L)生产的CMO,在实验基础上测试这些菌株的生产能力。公共卫生相关性:“扩大细菌微细胞生产”Vaxiion Therapeutics,Inc.专注于将几种专有的基于细菌微细胞的产品推向市场。Vaxiion已经将细菌微细胞平台技术定位于疫苗开发,癌症治疗的靶向递送和早期体内靶向肿瘤生物成像。虽然这三个项目都在各自的临床前开发阶段取得了进展,但如果要将微细胞推向市场,所有这些产品都必须解决一个至关重要的问题。问题是Vaxiion是否有能力扩大生产和纯化,以满足所有这些产品的预期需求。如果为第一阶段SBIR赠款提案提供资金,将用于解决生产问题,而第二阶段将主要集中在大规模生产和纯化上。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Matthew Giacalone其他文献

Matthew Giacalone的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Matthew Giacalone', 18)}}的其他基金

Immunotherapeutic minicells for use in intermediate and high-risk non-muscle inva
用于中度和高风险非肌肉侵袭的免疫治疗小细胞
  • 批准号:
    8920852
  • 财政年份:
    2013
  • 资助金额:
    $ 13万
  • 项目类别:
Immunotherapeutic minicells for use in intermediate and high-risk non-muscle inva
用于中度和高风险非肌肉侵袭的免疫治疗微细胞
  • 批准号:
    8646400
  • 财政年份:
    2013
  • 资助金额:
    $ 13万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了